Posted by Michael Wonder on 26 Jan 2018
Institute for Clinical and Economic Review releases draft evidence report on emicizumab for haemophilia A
26 January 2018 - Public comment period now open until 23 February 23; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review today released a draft evidence report assessing the comparative clinical effectiveness and value of emicizumab (Hemlibra, Genentech). Emicizumab was approved by the FDA in November of 2017 for prevention of bleeding in adults and children who have haemophilia A with coagulation factor VIII inhibitors.
Factor VIII is the clotting protein that is deficient in those with haemophilia A, and inhibitors interfere with the factor replacement therapy that would typically be used to treat the condition.
